Application for Admission to Trading

MGC Pharmaceuticals Limited

02 August 2023

 

MGC Pharmaceuticals Ltd

Compliance Release - Application for Admission to Trading

2 August 2023

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ("MGC Pharma" or the "Company") is applying for admission to the Financial Conduct Authority's Official List and to trading on the Main Market of London Stock Exchange plc ("Admission) of 87,353,469 fully paid Ordinary Shares ("Shares") previously issued by MGC Pharma. Admission  of the Shares is expected to take place at 8:00am (British Summer Time) on 9 August 2023.

Details of the 87,353469 Shares for which these applications have been lodged are as follows:

·      21,511,545 shares issued to Mercer in 2022 pursuant to a financing agreement.

·      65,841,924 shares issued in 2022 as consideration for the 40% acquisition of ZAM Software Limited.

The Shares are already quoted on the ASX and application for Admission will not affect the Total Voting Rights in the Company.

-Ends-

Authorised for release by the Managing Director, for further information please contact:

MGC Pharmaceuticals Ltd      Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd Rowan Harland Company Secretary [phone] [e-mail]
UK IR/PR Advisers  IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen [phone] [e-mail]	UK Brokers Oberon Capital Aimee McCusker / Adam Pollock [phone] [e-mail] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant derived medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant derived medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development. 

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant derived medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities. 

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceutica

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

END